Vanikar Aruna
G.R. Doshi and K.M. Mehta Institute of Kidney Diseases & Research Centre and Dr. H.L. Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Asarwa, Ahmedabad, India.
J Nephropathol. 2014 Jan;3(1):18-21. doi: 10.12860/jnp.2014.04. Epub 2014 Jan 1.
Implication for health policy/practice/research/medical education: Transplantation is now a well-accepted therapy for end organ failure. However the recipients are required to take life-long immunosuppression to prevent rejection. This leads to immunosuppression associated morbidity in the form of viral/ fungal/ bacterial infections in addition to causing financial burden on the system. Over a long run these patients are at high risk to develop malignancies.In spite of all these efforts, the graft is lost over 7-10 years to chronic graftattrition/ rejection. The only answer to this problem is "Transplant tolerance" which means stable allograft function while maintaining third party immuneresponse intact in absence of rejections on no immunosuppression. Since last 60 years transplanters across the globe are in search of this "Mackenna's gold". The following editorial discusses how far have we progressed in our search for the promised land of "Transplant Tolerance."
对卫生政策/实践/研究/医学教育的启示:移植如今已成为终末期器官衰竭被广泛接受的治疗方法。然而,接受者需要终身服用免疫抑制剂以防止排斥反应。这不仅会导致免疫抑制相关的发病率,表现为病毒/真菌/细菌感染,还会给医疗系统带来经济负担。从长远来看,这些患者发生恶性肿瘤的风险很高。尽管付出了所有这些努力,但移植物仍会在7至10年内因慢性移植物损耗/排斥反应而丧失功能。解决这个问题的唯一答案是“移植耐受”,即在不进行免疫抑制且无排斥反应的情况下,维持第三方免疫反应完整的同时保持同种异体移植物功能稳定。在过去的60年里,全球的移植医生都在寻找这个“麦肯纳的宝藏”。以下社论讨论了在寻找“移植耐受”这片乐土的征程中我们取得了多大进展。